For the quarter ending 2025-09-30, COYA made $3,881,320 in revenue. -$2,115,831 in net income. Net profit margin of -54.51%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | - | 6,578,134 | 7,934,806 | 4,450,289 |
| Collaboration revenue | 3,564,254 | 163,616 | 257,884 | - |
| Total research and development expenses | 2,916,875 | 3,663,103 | 5,214,076 | 2,223,903 |
| In-process research and development | 515,996 | - | - | - |
| Total general and administrative expenses | 2,557,440 | 2,908,191 | 2,713,890 | 2,219,545 |
| Loss from operations | - | -6,414,518 | -7,676,922 | -4,450,289 |
| Depreciation | 6,840 | 6,840 | 6,840 | 6,841 |
| Other income | 317,066 | 319,541 | 370,165 | 428,871 |
| Pre-tax loss | - | -6,094,977 | -7,306,757 | - |
| Income tax expense | - | 0 | - | - |
| Net loss | -2,115,831 | -6,094,977 | -7,306,757 | -4,021,418 |
| Earnings per share, basic | -0.13 | -0.36 | -0.44 | -0.26 |
| Earnings per share, diluted | -0.13 | -0.36 | -0.44 | -0.26 |
| Weighted average number of shares outstanding, basic | 16,732,766 | 16,724,998 | 16,720,511 | 15,221,308 |
| Weighted average number of shares outstanding, diluted | 16,732,766 | 16,724,998 | 16,720,511 | 15,221,308 |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)